FLT3 and acute myeloid leukemia: For patients considered eligible for intensive chemotherapy, with a diagnosis of AML-MRC and concomitant FLT3 mutation, 80% of the clinicians opted for targeted induction treatment (“7+3” regimen plus midostaurin) (31) rather than an AML-MRC-specific treatment such as CPX-351 (32).